Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
2 other identifiers
interventional
503
32 countries
170
Brief Summary
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started May 2014
170 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2014
CompletedFirst Posted
Study publicly available on registry
April 7, 2014
CompletedStudy Start
First participant enrolled
May 6, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 25, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
October 20, 2016
CompletedResults Posted
Study results publicly available
August 18, 2017
CompletedJanuary 5, 2018
January 1, 2018
2.2 years
April 2, 2014
July 21, 2017
January 3, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT
Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time (dTT) or ecarin clotting time (ECT), at any time point from the end of the first infusion up to 4 hours after the last infusion. Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients). Reversal is calculated as 100\* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is \> 100, it was set to 100.
from the end of the first infusion up to 4 hours after the last infusion on Day 1
Secondary Outcomes (6)
Reversal of aPTT and TT From Central Laboratory
from the end of the first infusion up to 4 hours after the last infusion on Day 1
Duration of Reversal
from the first infusion up to 24 hours after the last infusion on Day 1
Occurrence of Major/Life-threatening/Fatal Bleeding (for Group B Only) Intraoperatively
within 24 hours of surgery
Time to Cessation of Bleeding (for Group A Only)
from the first infusion up to 24 hours after the last infusion on Day 1
Cmin,1 of Unbound Sum (Free) Dabigatran
Since the end of first vial of idarucizumab up to 4 hours after the completion of second vial
- +1 more secondary outcomes
Study Arms (1)
idarucizumab
EXPERIMENTALidarucizumab Only 1 treatment, no placebo or comparator
Interventions
Eligibility Criteria
You may qualify if:
- Group A (Bleeding patients)
- Overt bleeding judged by the physician to require a reversal agent
- Currently taking dabigatran etexilate
- At least 18 years of age
- Written informed consent
- Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding
- Condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.
- Current treatment with dabigatran
- At least 18 years of age
- Written Informed consent.
You may not qualify if:
- Group A (Bleeding Patients)
- Patients with minor bleeds (epistaxis, hematuria) who can be managed with standard supportive care.
- Patients with no clinical signs of bleeding
- Contraindications to study medication including known hypersensitivity to the drug or its excipients.
- Group B (Patients who require emergency surgery or procedure)
- A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.
- Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (176)
Baptist Health Center for Clinical Research
Little Rock, Arkansas, 72205, United States
Loma Linda University Medical Center
Loma Linda, California, 92354, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010-2975, United States
University of Florida College of Medicine
Gainesville, Florida, 32610, United States
Baptist Medical Center
Jacksonville, Florida, 32207, United States
Mayo Clinic Cancer Center
Jacksonville, Florida, 32224, United States
Tampa General Hospital
Tampa, Florida, 33606, United States
St. Joseph's Hospital
Tampa, Florida, 33607, United States
Northwestern University
Chicago, Illinois, 60611, United States
OSF Saint Francis Medical Center
Peoria, Illinois, 61637, United States
IU Health Methodist Hospital
Indianapolis, Indiana, 46202, United States
Community Hospital
Munster, Indiana, 46321, United States
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, 70808, United States
Newton-Wellesley Hospital
Newton, Massachusetts, 02462, United States
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439, United States
Henry Ford Allegiance Health
Jackson, Michigan, 49201, United States
Mercy Hospital St. Louis
St Louis, Missouri, 63141, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
University of Cincinnati
Cincinnati, Ohio, 45219, United States
Miami Valley Hospital
Dayton, Ohio, 45409, United States
St. Elizabeth Youngstown Hospital
Youngstown, Ohio, 44501, United States
St. John Health System Inc
Tulsa, Oklahoma, 74104, United States
St. Mary Medical Center
Langhorne, Pennsylvania, 19047, United States
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096, United States
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Texas Health Research and Education Institute
Fort Worth, Texas, 76104, United States
Memorial Hermann Hospital - Texas Medical Center
Houston, Texas, 77030, United States
Sentara RMH Medical Center
Harrisonburg, Virginia, 22801, United States
Virginia Commonwealth University
Richmond, Virginia, 23298-0401, United States
Centro Privado de Cardiología
San Miguel de Tucumán, ZC4000, Argentina
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
St George Hospital
Kogarah, New South Wales, 2217, Australia
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia
Westmead Hospital-Clinical Haematology Dept
Westmead, New South Wales, 2145, Australia
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
St. Vincents Hospital (MEL)
Fitzroy, Victoria, 3065, Australia
KH der Barmherzigen Schwestern Linz
Linz, 4010, Austria
Kepler Univ. Klinikum Linz
Linz, 4020, Austria
AKH - Medical University of Vienna
Vienna, 1090, Austria
Wilhelminenspital
Vienna, 1160, Austria
Aalst - HOSP Onze-Lieve-Vrouw
Aalst, 9300, Belgium
Brussels - UNIV St-Pierre
Brussels, 1000, Belgium
Brussels - UNIV UZ Brussel
Brussels, 1090, Belgium
Brussels - UNIV St-Luc
Brussels, 1200, Belgium
Genk - HOSP ZOL (St-Jan)
Genk, 3600, Belgium
UZ Leuven
Leuven, 3000, Belgium
Hospital Nossa Senhora de Pompéia
Caxias do Sul, 95010-005, Brazil
St. Paul's Hospital
Vancouver, British Columbia, V1Y 1S1, Canada
Jewish General Hospital
Montreal, Migration Data, H3T 1E2, Canada
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2, Canada
Juravinski Hospital
Hamilton, Ontario, L8V 5C2, Canada
Fundación Valle del Lili
Cali, 760032, Colombia
Centro Médico Imbanaco de Cali S.A.
Cali, 760042, Colombia
Fundación Cardiovascular de Colombia
Floridablanca, Colombia
Hospital Pablo Tobón Uribe
Medellín, 50034, Colombia
University Hospital Brno
Brno, 625 00, Czechia
Hospital,Neurology Dept,Ceske Budejovice
České Budějovice, 370 01, Czechia
Hospital Hradec Kralove
Hradec Králové, 500 05, Czechia
Regional Hospital Liberec
Liberec, 460 63, Czechia
Univ. Hospital Kralovske Vinohrady
Prague, 100 34, Czechia
University Hospital Motol
Prague, 150 06, Czechia
Aarhus Universitetshospital
Aarhus C, 8000, Denmark
HUS, Kirurginen päivystysosasto P1P, Meilahti, Helsinki
Helsinki, 00290, Finland
Keski-Suomen keskussairaala
Jyväskylä, 40620, Finland
Oulun yliopistollinen keskussairaala
Oulu, 90220, Finland
TAYS, Acuta, Tampere
Tampere, 33521, Finland
TYKS, Akuutti sisätautihoito ASIS, Turku
Turku, 20521, Finland
HOP Trousseau
Chambray-lès-Tours, 37170, France
HOP Bocage
Dijon, 21079, France
HOP André Mignot
Le Chesnay, 78150, France
HOP Lille, SAMU 59, Lille
Lille, 59037, France
HOP Dupuytren
Limoges, 87042, France
HOP Herriot
Lyon, 69003, France
HOP Lapeyronie
Montpellier, 34295, France
HOP Haut-Lévêque
Pessac, 33604, France
HOP Lyon Sud
Pierre-Bénite, 69495, France
HOP Nord
Saint-Priest-en-Jarez, 42270, France
HOP Sainte Anne, Urgence, Toulon
Toulon, 83041, France
Vivantes Netzwerk für Gesundheit GmbH
Berlin, 12351, Germany
Universitätsmedizin Greifswald
Greifswald, 17475, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, 55131, Germany
Pamela Youde Nethersole Eastern Hospital
Hong Kong, 0, Hong Kong
Prince of Wales Hospital
Hong Kong, 0, Hong Kong
Prince of Wales Hosp, Dept of Med & Therapeutics
Hong Kong, Hong Kong
B.M. Birla Heart research Centre
Kolkata, 700027, India
Fortis Escorts Heart Institute
New Delhi, 110025, India
St James's Hospital
Dublin, DUBLIN 8, Ireland
Cork University Hospital
Wilton, Ireland
Rambam Medical Center
Haifa, 3109601, Israel
Meir Medical Center
Kfar Saba, 44281, Israel
The Chaim Sheba Medical Center Tel Hashomer
Ramat Gan, 52621, Israel
Sourasky Medical Center
Tel Aviv, 64239, Israel
Azienda Ospedaliera Careggi
Florence, 50134, Italy
Ospedale S.Maria della Misericordia, AO di Perugia
Perugia, 06132, Italy
Azienda Unità Sanitaria Locale di Reggio Emilia
Reggio Emilia, 42123, Italy
Policlinico Gemelli
Roma, 00168, Italy
Az. Osp. S.Giovanni-Addolorata
Roma, 00184, Italy
Japanese Red Cross Nagoya Daini Hospital
Aichi, Nagoya, 466-8650, Japan
Ehime Prefectural Central Hospital
Ehime, Matsuyama, 790-0024, Japan
Fukuoka Tokushukai Medical Center
Fukuoka, Kasuga, 816-0864, Japan
Ogaki Municipal Hospital
Gifu, Ogaki, 503-8502, Japan
National Hospital Organization Takasaki General Medical Center
Gunma, Takasaki, 370-0829, Japan
Hyogo College of Medicine Hospital
Hyogo, Nishinomiya, 663-8501, Japan
National Hospital Organization Kagoshima Medical Center
Kagoshima, Kagoshima, 892-0853, Japan
Shonan Kamakura General Hospital
Kanagawa, Kamakura, 247-8533, Japan
National Cerebral and Cardiovascular Center
Osaka, Suita, 565-8565, Japan
Nippon Medical School Hospital
Tokyo, Bunkyo-Ku, 113-8603, Japan
National Hospital Organization Disaster Medical Center
Tokyo, Tachikawa, 190-0014, Japan
Yamagata City Hospital SAISEIKAN
Yamagata, Yamagata, 990-8533, Japan
Hospital Cardiologica Aguascalientes
Aguascalientes, 20297, Mexico
OLVG, locatie Oosterpark
Amsterdam, 1091 AC, Netherlands
Academisch Medisch Centrum (AMC)
Amsterdam, 1105 AZ, Netherlands
Martini Ziekenhuis
Groningen, 9728 NT, Netherlands
Maastricht Universitair Medisch Centrum
Maastricht, 6229 ER, Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
Erasmus Medisch Centrum
Rotterdam, 3015 CE, Netherlands
Christchurch Hospital
Christchurch, 8011, New Zealand
Auckland City Hospital
Grafton / Auckland, 1023, New Zealand
Waikato Hospital
Hamilton, 3240, New Zealand
Middlemore Hospital
Otahuhu South Auckland, 2025, New Zealand
North Shore Hospital, Takapuna
Takapuna Auckland, 0620, New Zealand
Haukeland Universitetssykehus
Bergen, N-5021, Norway
Vestre Viken HF, Drammen Sykehus
Drammen, N-3004, Norway
Sykehuset Østfold Kalnes
Grålum, N-1714, Norway
Oslo Universitetssykehus HF, Ullevål sykehus
Oslo, N-0424, Norway
Universitetssykehuset Nord-Norge, Tromsø
Tromsø, N-9038, Norway
Univ. Clinic Hosp, Bialystok
Bialystok, 15276, Poland
University Clinical Center, Gdansk
Gdansk, 80952, Poland
Saint Wincenty a Paulo Hosp., Cardiology Dept., Gdynia
Gdynia, 81348, Poland
Reg.Hosp Kielce,Swietokrzyskie,1.Clinic of Cardiology,Kielce
Kielce, 25736, Poland
The John Paul II Hosp.,Dept.of Coronary Heart Disease,Krakow
Krakow, 31202, Poland
Stefan Kardynal Wyszynski Reg.Hosp,Cardiol&IntensUnit,Lublin
Lublin, 20718, Poland
Independent Public Healthcare, Dept. of Cardiology, Pulawy
Puławy, 24100, Poland
Central Hosp.Minis.Interior,Dep.Noninvasive Cardiol,Warszawa
Warsaw, 02507, Poland
Centro Hospitalar da Cova da Beira Hospital Pêro da Covilhã
Covilha, 6200-251, Portugal
CHLO, EPE - Hospital S. Francisco Xavier
Lisbon, 1495-005, Portugal
Centro Hospitalar do Porto, EPE
Porto, 4099-001, Portugal
Centro Hospitalar São João,EPE
Porto, 4202-451, Portugal
Military Medical Academy n.a. S. M. Kirov, St. Petersburg
Saint Petersburg, 194175, Russia
City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg
Saint Petersburg, 199 106, Russia
National University Hospital
Singapore, 119074, Singapore
Singapore General Hospital
Singapore, 169608, Singapore
Changi General Hospital
Singapore, 529889, Singapore
Dr. D. Adler
Sandton, 2021, South Africa
Dr. Engelbrecht
Somerset West, 7130, South Africa
Seoul National University Bundang Hospital
Seongnam, 463-707, South Korea
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, 137-701, South Korea
Hospital General Universitario de Alicante
Alicante, 03010, Spain
Hospital Vall d'Hebron
Barcelona, 08035, Spain
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Hospital de Bellvitge
Barcelona, 08907, Spain
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
Hospital Ramón y Cajal
Madrid, 28034, Spain
Hospital Clínico San Carlos
Madrid, 28040, Spain
Hospital La Paz
Madrid, 28046, Spain
Hospital Regional Universitario de Málaga
Málaga, 29010, Spain
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
Hospital Politècnic La Fe
Valencia, 46009, Spain
Hospital Clínico de Valencia
Valencia, 46010, Spain
Hospital Álvaro Cunqueiro
Vigo (Pontevedra), 36312, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, 50009, Spain
Sahlgrenska US, Göteborg
Gothenburg, 413 45, Sweden
Skånes universitetssjukhus
Lund, 221 85, Sweden
Akademiska sjukhuset
Uppsala, 751 85, Sweden
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
Far Eastern Memorial Hospital
New Taipei City, 220, Taiwan
National Taiwan University Hospital
Taipei, 100, Taiwan
Taipe Veterans General Hospital
Taipei, 11217, Taiwan
North Hampshire Hospital
Basingstoke, RG24 9NA, United Kingdom
Royal Liverpool University Hospital
Liverpool, L7 8XP, United Kingdom
Royal London Hospital
London, E1 1ES, United Kingdom
St George's Hospital
London, SW17 0QT, United Kingdom
Emergency Department, John Radcliffe Hospital, Oxford
Oxford, OX3 9DU, United Kingdom
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
Musgrove Park Hospital
Taunton, TA1 5DA, United Kingdom
Related Publications (6)
Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, Pollack CV, Weitz JI. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019 Oct 8;74(14):1760-1768. doi: 10.1016/j.jacc.2019.07.070.
PMID: 31582135DERIVEDGlund S, Coble K, Gansser D, Stangier J, Hoermann K, Pollack CV, Reilly P. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. J Thromb Haemost. 2019 Aug;17(8):1319-1328. doi: 10.1111/jth.14476. Epub 2019 Jun 18.
PMID: 31050868DERIVEDVan der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S, Elsaesser A, Klok FA, Pollack CV Jr, Huisman MV. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation. 2019 Feb 5;139(6):748-756. doi: 10.1161/CIRCULATIONAHA.118.036710.
PMID: 30586692DERIVEDPollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
PMID: 28693366DERIVEDPollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
PMID: 26095746DERIVEDPollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul;114(1):198-205. doi: 10.1160/TH15-03-0192. Epub 2015 May 28.
PMID: 26020620DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Boehringer Ingelheim, Call Center
- Organization
- Boehringer Ingelheim
Study Officials
- STUDY CHAIR
Boehringer Ingelheim
Boehringer Ingelheim
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 2, 2014
First Posted
April 7, 2014
Study Start
May 6, 2014
Primary Completion
July 25, 2016
Study Completion
October 20, 2016
Last Updated
January 5, 2018
Results First Posted
August 18, 2017
Record last verified: 2018-01